COVID Immune
The COVID Immune study aims to investigate whether pre-COVID immune phenotypes and biomarkers predict susceptibility to and severity of SARS-CoV-2 infection in extant longitudinal LifeCourse population cohorts of children aged 1 to 24 years and their household. In addition, there is an opportunity to further understand the clinical features, natural history and long-term effects of SARS-CoV-2 infection on immunological and other biomarkers; and the psychosocial impacts of SARS-CoV-2 and its management.
Year | 2020: Baseline | 2021: Follow-up (12 mths after baseline) | |||||||
---|---|---|---|---|---|---|---|---|---|
Cohort | VITALITY | MIS BAIR | HealthNuts | SchoolNuts clinical | VITALITY | MIS BAIR | HealthNuts | SchoolNuts clinical | |
Age | 1-5 yrs | 5-6 yrs | 10-14 yrs | 15-24 yrs | 2-6 yrs | 6-7 yrs | 11-15 yrs | 16-25 yrs | |
# | 377 | 315 | 418 | 63 | TBC | TBC | TBC | TBC | |
Allergies | Allergies | ||||||||
Behavioural problems | Behavioural problems | ||||||||
Demographics | |||||||||
Education and childcare | |||||||||
Environmental exposures | |||||||||
General health | |||||||||
Home and neighbourhood environments | |||||||||
Medications and supplements | |||||||||
Mental health | |||||||||
Puberty | Puberty | ||||||||
Relationships | |||||||||
Resilience and wellbeing | |||||||||
Substance use | |||||||||
Biosamples |
Study Summary | |
---|---|
Study name | COVID Immune: Predictors of infection and clinical severity with SARS-CoV-2 in extant longitudinal LifeCourse population cohorts of children/young adults and their household/family contacts |
Current principal investigator/s | Prof David Burgner (Co – Study Principal Investigator) A/Prof Kirsten Perrett (Co – Study Principal Investigator) |
Current project manager | Ms Megan Mathers |
Primary Institution | Murdoch Children’s Research Institute |
Major funding sources | Rio Tinto Department of Health and Human Services, the Victor Chiodo Foundation, and Morgan Stanley (Psychosocial aspects) |
Are data available to others outside study team? | Certain data may be available upon Investigator agreement only |
Study focus (e.g. social development) | To investigate predictors of infection and clinical severity with SARS-CoV-2 in extant longitudinal LifeCourse population cohorts of children aged 1 to 24 years and their household. |
Sampling frame | Children/young adults aged 1 to 24 years from each of 4 established cohorts with existing pre-pandemic immune biospecimens (including PBMCs and/or plasma) Children/young adult ages range from: 1 to 5 years of age (Vitality), 5 to 6 years of age (MIS BAIR), 10 to 14 years (HealthNuts) and 15 to 24 years (SchoolNuts) |
Study type (e.g. randomised control trial, cohort, case-control) | Longitudinal cohort study |
Year commenced | 2020 |
Ongoing recruitment? | No |
Commencement sample (N) | 1172 |
Intergenerational (e.g. offspring)? | No |
Imaging (e.g. fMRI, ultrasound, retinal photograph)? | No |
Linkage (e.g. BioGrid, VPDC, NAPLAN, Medicare)? | No |
Biosamples (e.g. buccal, blood, hair)? | Blood |
Ethics approvals or requirements (e.g. specific, extended, unspecified, other)? | Specific consent for psychosocial questionnaire data, unspecified consent for blood samples to be used in future ethically approved projects related to infection, allergy, immune responses and child health |
Principal Investigators
Prof David Burgner
A/Prof Kirsten Perrett
Project Manager
Ms Megan Mathers
Study Contact
(03) 9936 6029
covid.immune@mcri.edu.au
Postal Address
Murdoch Children’s Research Institute
The Royal Children’s Hospital, 50 Flemington Road
Parkville, Victoria 3052 Australia